Titan Biotech Ltd Plans Stock Split to Improve Liquidity and Attract Retail Investors

Titan Biotech Ltd, a small-cap company in the specialty chemical sector, has announced a stock split. The Board of Directors decided on 29th November 2025 to divide each Rs 10 equity share into five shares of Rs 2 each. This move awaits approval from the company's members. The record date for this 5:1 stock split will be communicated after receiving member approval.

The primary aim of Titan Biotech's stock split is to enhance liquidity and make shares more accessible to individual investors. By reducing the face value from Rs 10 to Rs 2, the company hopes to attract more retail investors. Post-split, the authorised share capital will rise from 1 crore shares of Rs 10 each to 5 crore shares of Rs 2 each. The issued and paid-up share capital will increase from 82,63,700 shares to 4,13,18,500 shares, maintaining the same total capital value.

"To enhance the liquidity of the company's equity shares and to encourage participation of retail investors by making equity shares of the Company more affordable," stated Titan Biotech in a filing with the stock exchange. The company expects the share split process to conclude within two months, contingent on shareholder approval.

Financially, Titan Biotech reported a revenue increase in the September 2025 quarter. Revenue from operations reached Rs 54.35 crore, marking a 36.26% rise from Rs 39.89 crore in September 2024. Net profit for September 2025 was Rs 6.86 crore, up by 37.15% from Rs 5 crore in September 2024. EBITDA also grew by 31.81%, reaching Rs 10.65 crore in Q2FY26 compared to Rs 8.08 crore in Q2FY25.

A R Ramachandran, an Independent SEBI registered Research Analyst at Tips2trades, commented on Titan Biotech's stock performance: "Titan Biotech stock price is bearish on the Daily charts with strong resistance at 1074. A Daily close below support of 930 could lead to a target of 866 in the near term."

The company's decision to split its shares aims to make them more affordable and attractive to retail investors while maintaining overall capital value. This strategic move reflects Titan Biotech's commitment to enhancing market participation and improving share liquidity.